<DOC>
	<DOCNO>NCT02344277</DOCNO>
	<brief_summary>Brugada syndrome inherit arrhythmia syndrome increase risk syncope sudden death result episode polymorphic ventricular tachychardia fibrillation . Currently , medical therapy Brugada syndrome treatment available implantation ICD . There discussion interest ICD implantation secondary prevention patient experience syncope best therapeutic difficult draw asymptomatic patient . Recently demonstrate asymptomatic patient spontaneous type 1 aspect Brugada syndrome , ( ) significant risk ventricular arrhythmia , ( ii ) problem inappropriate shock solve good ICD programming ( iii ) problem lead failure remain main problem young population active represent main limitation large indication ICD implantation population long life expectancy patient normal life expectancy except risk ventricular arrhythmia . In context S-ICD System ( Boston Scientific Inc. ) implantable defibrillator technology treat ventricular tachyarrhythmias use subcutaneous pulse generator electrode system rather transvenous lead system , represent attractive opportunity give possibility protect patient risk ventricular arrhythmia risk lead failure . However , new technology Brugada syndrome patient specific population ( active patient , specific change time ECG aspect risk T wave sense high risk SVT ) , seem important evaluate effectiveness safety S-ICD specific context .</brief_summary>
	<brief_title>Evaluation Subcutaneous Implantable Cardiac Defibrillator Brugada Patients</brief_title>
	<detailed_description />
	<mesh_term>Brugada Syndrome</mesh_term>
	<criteria>Patient type I Brugada syndrome eligible implantation SICD system : Symptomatic : ( history resuscitate sudden death , syncope ) ECG show aspect Brugada syndrome type I pharmacological test ( ajmaline flecainide test ) accord criterion consensus conference ECG validation Clinical Events Committee expert . Asymptomatic : aspect spontaneous type I Brugada syndrome ECG validation Clinical Events Committee expert . Brugada syndrome patient Indication ICD replacement . No contraindication SICD implantation ( anatomic physiologic criterion ) particular attention validation ECG prescreening implantation . For study least 2 vector must suitable SICD implantation . Patients whose age 18 year , legal age give inform consent specific state national law . Patients willing capable providing informed consent , participate test associate clinical investigation approve clinical investigational center . Incessant ventricular tachycardia ( VT ) and/or document spontaneous , frequently recur VT reliably terminate antitachycardia pacing . Patients unipolar pacemaker implant device revert unipolar pacing . Presence severe medical condition patient expect survive plan study followup period . Minor , patient trusteeship guardianship . Patients currently participate investigational drug device clinically interfere SICDBrugada registry study endpoint result . Female childbearing potential without adequate contraception time implantation . Inability comply followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Subcutaneaous Implantable Cardiac Defibrillator</keyword>
	<keyword>Brugada syndrome</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Safety</keyword>
</DOC>